Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19

Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing coronavirus disease (COVID-19). Because of the close relationship between metabolic diseases such as type 2 diabetes mellitus and obesity and the pre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World journal of gastroenterology : WJG Ročník 27; číslo 33; s. 5502
Hlavní autoři: Campos-Murguía, Alejandro, Román-Calleja, Berenice M, González-Regueiro, José A, Hurtado-Díaz-de-León, Ivonne, Solís-Ortega, Alberto Adrián, Flores-García, Nayelli C, García-Juárez, Ignacio, Ruiz-Margáin, Astrid, Macías-Rodríguez, Ricardo Ulises
Médium: Journal Article
Jazyk:angličtina
Vydáno: 07.09.2021
ISSN:2219-2840, 2219-2840
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing coronavirus disease (COVID-19). Because of the close relationship between metabolic diseases such as type 2 diabetes mellitus and obesity and the presence of metabolic-associated fatty liver disease (MAFLD), a high number of cases of patients affected by both MAFLD and COVID-19 would be expected, especially in high-risk populations. Some studies have shown an increased risk of adverse clinical outcomes, viral shedding, and deep vein thrombosis, especially in patients with MAFLD- related liver fibrosis. The predisposition to poor outcomes and severe acute respiratory syndrome coronavirus 2 infection in patients with MAFLD could be secondary to mechanisms common to both, including preexisting systemic chronic inflammation, endothelial dysfunction, and involvement of the renin-angiotensin system. Because of the increased risk of adverse outcomes, MAFLD should be screened in all patients admitted for COVID-19. Available computed tomography scans could be of help, assessment of liver fibrosis is also recommended, favoring noninvasive methods to limit the exposure of healthcare workers. Liver involvement in this population ranges from abnormalities in liver chemistry to hepatic steatosis in postmortem biopsies. Finally, preventive measures should be strongly advocated in patients already known to have MAFLD, including the use of telemedicine and vaccination in addition to general measures.Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing coronavirus disease (COVID-19). Because of the close relationship between metabolic diseases such as type 2 diabetes mellitus and obesity and the presence of metabolic-associated fatty liver disease (MAFLD), a high number of cases of patients affected by both MAFLD and COVID-19 would be expected, especially in high-risk populations. Some studies have shown an increased risk of adverse clinical outcomes, viral shedding, and deep vein thrombosis, especially in patients with MAFLD- related liver fibrosis. The predisposition to poor outcomes and severe acute respiratory syndrome coronavirus 2 infection in patients with MAFLD could be secondary to mechanisms common to both, including preexisting systemic chronic inflammation, endothelial dysfunction, and involvement of the renin-angiotensin system. Because of the increased risk of adverse outcomes, MAFLD should be screened in all patients admitted for COVID-19. Available computed tomography scans could be of help, assessment of liver fibrosis is also recommended, favoring noninvasive methods to limit the exposure of healthcare workers. Liver involvement in this population ranges from abnormalities in liver chemistry to hepatic steatosis in postmortem biopsies. Finally, preventive measures should be strongly advocated in patients already known to have MAFLD, including the use of telemedicine and vaccination in addition to general measures.
AbstractList Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing coronavirus disease (COVID-19). Because of the close relationship between metabolic diseases such as type 2 diabetes mellitus and obesity and the presence of metabolic-associated fatty liver disease (MAFLD), a high number of cases of patients affected by both MAFLD and COVID-19 would be expected, especially in high-risk populations. Some studies have shown an increased risk of adverse clinical outcomes, viral shedding, and deep vein thrombosis, especially in patients with MAFLD- related liver fibrosis. The predisposition to poor outcomes and severe acute respiratory syndrome coronavirus 2 infection in patients with MAFLD could be secondary to mechanisms common to both, including preexisting systemic chronic inflammation, endothelial dysfunction, and involvement of the renin-angiotensin system. Because of the increased risk of adverse outcomes, MAFLD should be screened in all patients admitted for COVID-19. Available computed tomography scans could be of help, assessment of liver fibrosis is also recommended, favoring noninvasive methods to limit the exposure of healthcare workers. Liver involvement in this population ranges from abnormalities in liver chemistry to hepatic steatosis in postmortem biopsies. Finally, preventive measures should be strongly advocated in patients already known to have MAFLD, including the use of telemedicine and vaccination in addition to general measures.Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing coronavirus disease (COVID-19). Because of the close relationship between metabolic diseases such as type 2 diabetes mellitus and obesity and the presence of metabolic-associated fatty liver disease (MAFLD), a high number of cases of patients affected by both MAFLD and COVID-19 would be expected, especially in high-risk populations. Some studies have shown an increased risk of adverse clinical outcomes, viral shedding, and deep vein thrombosis, especially in patients with MAFLD- related liver fibrosis. The predisposition to poor outcomes and severe acute respiratory syndrome coronavirus 2 infection in patients with MAFLD could be secondary to mechanisms common to both, including preexisting systemic chronic inflammation, endothelial dysfunction, and involvement of the renin-angiotensin system. Because of the increased risk of adverse outcomes, MAFLD should be screened in all patients admitted for COVID-19. Available computed tomography scans could be of help, assessment of liver fibrosis is also recommended, favoring noninvasive methods to limit the exposure of healthcare workers. Liver involvement in this population ranges from abnormalities in liver chemistry to hepatic steatosis in postmortem biopsies. Finally, preventive measures should be strongly advocated in patients already known to have MAFLD, including the use of telemedicine and vaccination in addition to general measures.
Author Solís-Ortega, Alberto Adrián
García-Juárez, Ignacio
González-Regueiro, José A
Ruiz-Margáin, Astrid
Campos-Murguía, Alejandro
Román-Calleja, Berenice M
Flores-García, Nayelli C
Hurtado-Díaz-de-León, Ivonne
Macías-Rodríguez, Ricardo Ulises
Author_xml – sequence: 1
  givenname: Alejandro
  surname: Campos-Murguía
  fullname: Campos-Murguía, Alejandro
– sequence: 2
  givenname: Berenice M
  surname: Román-Calleja
  fullname: Román-Calleja, Berenice M
– sequence: 3
  givenname: José A
  surname: González-Regueiro
  fullname: González-Regueiro, José A
– sequence: 4
  givenname: Ivonne
  surname: Hurtado-Díaz-de-León
  fullname: Hurtado-Díaz-de-León, Ivonne
– sequence: 5
  givenname: Alberto Adrián
  surname: Solís-Ortega
  fullname: Solís-Ortega, Alberto Adrián
– sequence: 6
  givenname: Nayelli C
  surname: Flores-García
  fullname: Flores-García, Nayelli C
– sequence: 7
  givenname: Ignacio
  surname: García-Juárez
  fullname: García-Juárez, Ignacio
– sequence: 8
  givenname: Astrid
  surname: Ruiz-Margáin
  fullname: Ruiz-Margáin, Astrid
– sequence: 9
  givenname: Ricardo Ulises
  surname: Macías-Rodríguez
  fullname: Macías-Rodríguez, Ricardo Ulises
BookMark eNpNjD1PwzAURS0EEm1hZ_TIQIL9nNjJiMJXpUpdgLVynBfqKnFCn9uKf08kGJjuudK9Z87OwxCQsRspUmWy4v60-0yPYFKvVJrnAs7YDECWCRSZOP_Hl2xOtBMClMphxk5V54N3tuMj7mlEF_0R6Y5bIiTqMcSJQ8N7dFsbPPXEh3Zq0dZD510y7QbnbcSGtzbGb95N_z1vPKEl5D7w0UY_aYiffNzyav2xfExkecUuWtsRXv_lgr0_P71Vr8lq_bKsHlaJU6BjUpcaSitKkZcFGKdbo9tMW6ed0VYVgLLOpLK6blFpdAYyiUIrWbRorFYNLNjtr3fcD18HpLjpPTnsOhtwONAGclPIHJTM4Adnw2OL
ContentType Journal Article
Copyright The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Copyright_xml – notice: The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
DBID 7X8
DOI 10.3748/wjg.v27.i33.5502
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 2219-2840
GroupedDBID ---
123
29R
2WC
36B
53G
5VR
7X8
8WL
AAKDD
ACGFO
AENEX
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
HYE
OK1
P2P
RNS
RPM
TR2
XSB
ID FETCH-LOGICAL-c326t-b9629a09059827c6f76f46ac6c76a382e1b413a6bfe36ec7241e06318fe7a63d2
IEDL.DBID 7X8
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000701735900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2219-2840
IngestDate Thu Jul 10 18:59:56 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 33
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c326t-b9629a09059827c6f76f46ac6c76a382e1b413a6bfe36ec7241e06318fe7a63d2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8433612
PQID 2578152314
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2578152314
PublicationCentury 2000
PublicationDate 20210907
PublicationDateYYYYMMDD 2021-09-07
PublicationDate_xml – month: 09
  year: 2021
  text: 20210907
  day: 07
PublicationDecade 2020
PublicationTitle World journal of gastroenterology : WJG
PublicationYear 2021
SSID ssj0023352
Score 2.3482842
SecondaryResourceType review_article
Snippet Metabolic diseases are highly prevalent worldwide and have been associated with adverse clinical outcomes, including mortality, in patients developing...
SourceID proquest
SourceType Aggregation Database
StartPage 5502
Title Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19
URI https://www.proquest.com/docview/2578152314
Volume 27
WOSCitedRecordID wos000701735900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV09T8MwELWAMrDwIUB8y0iMuE3sxE4mhAoIlsIAqFvlOA4KapNCQiv-PXep2w4sSGyJlMHyPd9d7vneEXIRCBWFoeAsVTZigbacJRbl8eJESI_bTMukGTaher2o34-fXMGtctcq5z6xcdRpabBG3kFoQawRfnA1_mA4NQrZVTdCY5W0BKQyiGrVX7AIHPuJcLgcnEoGbtib0ZQouNKZvr-1J1y1cyHakKTzX664iS93W_9d2TbZdJklvZ5BYYes2GKXTJ3u55COl12V1SXVC0FOeC5SOrLYAZxXo4qWGbzVgI1hbph21rMpzXRdf9Mh3uOgjtaheUGdMGtFsaJLu4-vDzdggj3ycnf73L1nbtYCM5DA1SyJJY-1F3so6KeMzJTMAqmNNEpqEXHrJxDuwHCZFdIaBYHfQnbjR5lVWoqU75O1oizsAaEhSsr4SRwKGwWB8DTq1cBfnqcMKgXxQ3I-38cBYBkJCl3Y8qsaLHfy6A_fHJMNjhdMkN1RJ6SVwXm1p2TdTOq8-jxroPADcU69kw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+perspectives%2C+assessment%2C+and+mechanisms+of+metabolic-associated+fatty+liver+disease+in+patients+with+COVID-19&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Campos-Murgu%C3%ADa%2C+Alejandro&rft.au=Rom%C3%A1n-Calleja%2C+Berenice+M&rft.au=Gonz%C3%A1lez-Regueiro%2C+Jos%C3%A9+A&rft.au=Hurtado-D%C3%ADaz-de-Le%C3%B3n%2C+Ivonne&rft.date=2021-09-07&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=27&rft.issue=33&rft.spage=5502&rft_id=info:doi/10.3748%2Fwjg.v27.i33.5502&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2219-2840&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2219-2840&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2219-2840&client=summon